In one paragraphArticle in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
17 authors.
Montserrat Puigdelloses Vallcorba *Department of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0001-6011-1755 Kavita Rawat *Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0002-9498-9723 Nishant Soni *Department of Genetics and Genomic Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-1567-0712 Angela DiMauro *Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0009-0009-9313-8693 Jacqueline D Chu *Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
Wes ThomasonDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Glaucia C FurtadoLipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Maya StrahlLipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0001-6244-1766 Junyan WuDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Tanvi JoshiDepartment of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.ORCID 0000-0001-7436-4673 Angelo AngioneDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0001-7713-5833 Gonzalo PiñeroDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Oren J BecherDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-4016-8492 James L RossDepartment of Neuroscience, University of Virginia School of Medicine, Charlottesville, VA 22908.
Alexander M TsankovDepartment of Genetics and Genomic Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Sergio A LiraLipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0002-6742-3089 Dolores HambardzumyanDepartment of Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029.ORCID 0000-0003-1975-4665 Funding
Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4MThe role of Myeloid cells in pediatric-high grade gliomasR01CA258636 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BECHER, OREN JOSH, HAMBARDZUMYAN, DOLORES · 2022 to 2025
$2.7MCOVID and Translational Science supercomputer (CATS)S10OD030463 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2021 to 2021
$2.0MHuman-mouse platform for data-driven patient stratification, target discovery, and validation in GBMR01CA308411 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Alexander Minchev Tsankov · 2026 to 2026
$683kHHS | NIH | National Cancer Institute (NCI) R01CA258636HHS | NIH | National Cancer Institute (NCI) R01CA308411NCATS NIH HHS UL1 TR004419NCI NIH HHS R01 CA258636NCI NIH HHS R01 CA308411NIH HHS S10 OD030463
6 · The paper itselfAbstract
Diffuse midline gliomas (DMGs) are highly aggressive, WHO grade 4 glial tumors that arise in midline central nervous system structures and are defined by K27M mutations in histone H3 genes. These K27M mutations shape intratumoral myeloid cell composition in DMG. In H3.1K27M DMGs, genetic ablation of monocyte recruitment reshapes the tumor microenvironment (TME) by reducing monocyte-derived macrophages (MDMs) and increasing microglia and neutrophil presence, with overall survival remaining unchanged, indicating compensatory myeloid remodeling is occurring. Here, by using CRISPR/Cas9-based genome editing, we generated a mouse model deficient for CCR1/CCR2/CCR3/CCR5 (Δ1235). Using this strain, we effectively abolished monocyte and MDM infiltration and reversed compensatory recruitment of CCR1+ neutrophils. Abolishing MDMs in tumors skewed remaining neutrophils and microglia toward a homeostatic state, reduced expression of immune checkpoint molecules on T cells, and extended the survival of H3.1K27M DMG-bearing mice. In contrast, H3.3K27M DMG showed independence from MDM recruitment, suggesting reliance on other TME-driven signaling. Last, H3.1K27M DMGs exhibited reduced microglia presence and a dose-dependent increase in MDM infiltration postirradiation. MDM depletion did not further enhance radiation efficacy, potentially due to compensatory recruitment of classical neutrophils. Collectively, these data reveal histone mutation-specific myeloid dependencies in DMG, highlighting MDM-independent mechanisms in H3.3K27M tumors and MDM-dependent pathways in H3.1K27M tumors.
Indexed as
Brain NeoplasmsGliomaHistonesMyeloid CellsAnimalsMacrophagesMiceMicrogliaMutationNeutrophilsTumor MicroenvironmentHistonesGliomamicrogliamonocyteneutrophilpediatric
Identifiers
PMID42594274
PMCPMC13486528
What OpenQuestion holds
Textmetadata
Read underepoch 390